We report the case of a full-term neonate who presented with cyanosis from birth secondary to methemoglobinemia precipitated by the obstetric use of bupivacaine in a spinal anaesthetic for caesarean delivery.
INTRODUCTION
Cyanosis in the newborn can be due to methemoglobinemia, an intra-erythrocytic hemoglobin abnormality. Methemoglobinemia is the presence of a higher than normal level of methemoglobin (MetHb) ferric (Fe3 þ ) rather than ferrous (Fe2 þ ) hemoglobin in the blood. MetHb has a decreased affinity for oxygen causing tissue hypoxia.
Methemoglobinemia can be inherited or acquired. Acquired methemoglobinemia is more common and occurs after exposure to an agent that oxidizes hemoglobin to MetHb. Inherited methemoglobinemia occurs when there is an enzyme cytochrome b5 reductase defect or with hemoglobin M disease. It also arises with pyruvate kinase and glucose-6-phosphate dehydrogenase deficiency. CASE A 3.1-kg male neonate was born at 39 þ 3 weeks gestation by emergency cesarean section for breech presentation. The mother was started on Labetalol at 38 weeks gestation for pregnancyinduced hypertension and no intrapartum antibiotics were given. Delivery otherwise followed an uneventful antenatal course with no significant family history.
Before delivery, a spinal anesthetic for maternal analgesia was administered containing 2.5 ml of 0.5% bupivacaine with 0.3 mg diamorphine (total 12.5 mg intrathecal bupivacaine dose). The mother subsequently developed a high spinal blockade resulting in a respiratory arrest requiring conversion to general anesthetic (using 350 mg thiopentone and 100 mg suxamethonium). Hypotension was managed with 400 mg phenylephrine. The mother's first arterial blood gas once intubated and ventilated was acidotic (pH 7.18, pCO2 6.2, base excess (BE) À 11, MetHb 1.2). She was transferred to intensive care unit and subsequently fully recovered.
At delivery, the neonate required cardiopulmonary resuscitation with intubation at 3 min of age. He self-extubated by 10 min of age. By 15 min of age, his oxygen saturations were 86% in air and required 50% fraction of inspired oxygen (FiO 2 ) by facial mask to maintain saturations above 95%. Normal clinical examination besides persisting clinical cyanosis not responding to supplemental oxygen. The umbilical cord gases were acceptable (arterial pH 7.27, BE À 3.5 and venous pH 7.31, BE À 2.8) but showed a raised MetHb (laboratory normal range o2% concentration of total Hb) of 12.5% on venous and 11.5% on arterial gas. He was transferred to the neonatal intensive care unit at 20 min of age.
On admission his capillary blood gas showed a raised MetHb of 12.4% (pH 7.28, pCO 2 6.3, BE À 4.9, lactate 3.2, glucose 4.7). An arterial blood gas at 1 h of life showed a partial pressure of oxygen (pO 2 ) of 11.3 kPa (pH 7.39, pCO 2 4.5, pO 2 11.3, BE À 4) and a calculated oxygen saturation of 93%. A repeat capillary blood gas at 7.5 h of life showed a mild compensated metabolic acidosis (pH 7.36, pCO 2 4.3, BE À 6) and a MetHb of 13.8%, taken 8 h from administration of maternal spinal anesthetic. He had a partial septic screen and received IV benzylpenicillin and gentamicin but was never thought be clinically septic. Chest X-ray and initial blood results were normal besides a borderline hemoglobin of 12.4 g dl À 1 . He initially required incubator oxygen (45% FiO 2 ) to maintain saturations measured by pulse oximeter above 95%, which was weaned over 36 h. Cyanosis resolved by 24 h of age but he continued to have a generalized grayish discoloration. The acidosis normalized by day two (pH 7.40, BE À 1). Maximum C-reactive protein was o5 mg l À 1 , blood culture was negative at 5 days incubation and he remained clinically well.
The methemoglobinemia persisted although improved and was monitored requiring no treatment. Maternal MetHb level was normal. His G6PD level, hemoglobin electrophoresis and blood film were normal. He was discharged home on day 4 with a MetHb of 11.4%.
On follow up, his MetHb was 8.4% on day 26 of life. At 2 months of life, further clinical assessment was normal, his Hb level was 9.5 g dl À 1 with a MetHb of 4.9%. Subsequent MetHb on day 301 of life was 1.3%. Enzymatic estimation of cytochrome b5 reductase was not performed as the prompt resolution and non-recurrence on follow up excludes enzyme deficiency as a cause.
DISCUSSION
Most cases in the literature report congenital causes. Recent reports of acquired methemoglobinemia where drugs have been identified as the causative factor, prilocaine, benzocaine and nitrate solutions are most widely reported. [1] [2] [3] Bupivacaine is a long-acting local anesthetic with rapid onset of action and a half-life in neonates of 8.1 h. His maximum MetHb level of 13.8% was at 8 h from administration of the spinal anesthetic. Bupivacaine is acknowledged as a cause of methemoglobinemia but not reported to occur following obstetric use. Kuhnert et al. acknowledged that bupivacaine crosses the placenta and metabolites can be found in the neonate's urine up to 36 h following delivery. 4 Whereas McGuinness et al. showed bupivacaine is detectable in the neonatal venous circulation from 4 h post-delivery up to 24 h after cesarean section. 5 Local anesthetics cross the placenta by passive diffusion. The higher the level of protein binding in the maternal circulation the less unbound drug there is to diffuse. Bupivacaine is widely used in obstetric practice as it has a low fetal/maternal ratio with a protein-binding capacity of up to 95%. However, if bupivacaine does enter the fetal circulation, it is proposed there is an increased risk of uptake in fetal tissues due to the high protein-binding capacity. 5 The rate of systemic absorption is dependent upon the total dose and concentration of drug administered, the route of administration and the vascularity of the administration site. As the systemic concentration increases the risk of complications from toxicity increases exponentially. The fetal pH affects the transfer of local anesthetics across the placenta. 6 In this case, the acidotic state of the mother secondary to intrapartum respiratory arrest will have compromised the neonate and may have increased his susceptibility to trans-placental transfer of bupivacaine.
Red blood cells contain approximately 1% MetHb levels (range: 0 to 3% MetHb). This is maintained by two mechanisms; the hexose-monophosphate shunt pathway and the nicotine adenine dinucleotide (NADH) diaphorase I and nicotine adenine dinucleotide phosphate (NADPH) diaphorase II system. The NADPH diaphorase II system can be pharmacologically activated. This is the basis for treatment of methemoglobinemia with methylene blue. The first line treatment for drug mediated methemoglobinaemia is stopping the offending oxidising agent. Treatment with methylene blue should be considered when the MetHb is 30% in an asymptomatic patient and 20% in a symptomatic patient unless significant co-morbidities exist in which case one would consider a lower treatment threshold. This neonate did not meet the criteria for treatment as his maximum MetHb was 13.8%. At MetHb concentrations of 3 to 10%, a slight grayish-blue discoloration of the skin may be present, asymptomatic clinical cyanosis occurs between 10 and 15% and at 20% or more cardiovascular and central nervous system symptoms occur.
Those under 3 months are particularly susceptible to acquired methemoglobinemia. The NADH diaphorase I system is immature. 7 The NADH cytochrome b5 reductase enzyme's activity and concentration are low. A study by Hjelt et al. measured the level of NADH reductase in all MetHb-positive patients in a neonatal intensive care unit. This was repeated 1 week after normalization of MetHb and the only significant difference was an increase in NADH reductase. 8 A study performed by Nilsson et al. demonstrated that the enzyme activity of cytochrome b5 reductase does not reach adult levels until 3 months of age. 9 The cytochrome (CYP3A4) involved in the metabolism of bupivacaine is immature in those younger than 6 months, accounting for delayed clearance 10 . Therefore, exposure to oxidizing drugs such as bupivacaine overwhelms the system and acutely increases MetHb levels.
This neonate most likely has lower oxygen saturations than recorded as the oxygen saturation values measured by a pulse oximeter are inaccurate and may be falsely elevated. An oxygen saturation gap, meaning a difference in calculated arterial oxygen saturation versus oxygen saturation by pulse oximetry, is a feature of methemoglobinaemia. Methemoglobin does not bind to oxygen, therfore the remaining oxyhemoglobin has a greater affinity for oxygen thus, shifting the oxygen-hemoglobin dissociation curve to the left resulting in tissue hypoxia and a functional anaemia.
In methemoglobinemia and as in this neonate, the MetHb percentage concentration of total hemoglobin is raised above 2% and the arterial partial oxygen pressure is normal. This is the diagnostic criteria of methemoglobinemia. Clinical examination and all further investigations were normal and therefore the Bupivacaine was the most likely causative agent for this neonate's methemoglobinemia.
CONCLUSION
Bupivacaine is the first-line anesthetic used in spinal anesthesia for cesarean delivery and physicians should therefore be aware of the potential complication of neonatal methemoglobinemia. The presentation of clinical cyanosis in a relatively well neonate in the absence of cardiopulmonary symptoms and normal pO 2 should alert clinicians to the possibility of methemoglobinemia.
